At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
Olaratumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Olaratumab and Doxorubicin for Neoplasm. Completed, enrolled 25 participants across 4 sites.
Detailed Summary
This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \[STS\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMar 2015
Primary CompletionAug 2018
Study CompletionJan 2020
TodayJul 2026
First PostedMar 4, 2015
Enrollment StartMar 23, 2015
Primary CompletionAug 27, 2018
Study CompletionJan 14, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.3 years ago
Interventions
Olaratumabbiological
Administered IV
Doxorubicindrug
Administered IV